Massachusetts health insurers are effectively telling the drug companies that they may seek a rapidly growing customer base ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan Skrmetti.

LynFit Nutrition is a recurring segment featured on“CT BUZZ,” where Metabolic Weight Loss & Fat Burning Expert, Lisa Lynn, ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

GLP-1 drugs alter taste perceptions, challenging food makers to adapt by enhancing umami flavours, balancing sweetness, and ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

GLP-1 drugs like Ozempic® and Zepbound® have gained significant attention for treating both diabetes and assisting with weight loss.